BMEDS
DEAD

Serial Number

90749761

Owner

Bayesian Biotech LLC

Attorney

Carole R. Klein

Filing Date

Jun 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BMEDS Trademark

Serial Number: 90749761

BMEDS is a trademark filed by Bayesian Biotech LLC on June 2, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently no longer active.

Owner Contact Info

Bayesian Biotech LLC (2 trademarks)

Basking Ridge, NJ 07920

Entity Type: 16

Trademark Details

Filing Date

June 2, 2021

Registration Date

Not Registered

Published for Opposition

March 29, 2022

Goods & Services

Downloadable computer software for use in calculating and tailoring the optimal individualized dosage for patients through blood samples from patients; downloadable computer software for use in mobile applications to develop model-informed precision dosing, track individualized dosing, generate population- and individual-based pharmacokinetic models, monitor clinical studies, determine optimal and lowest effective dosages of medication, develop risk evaluation and mitigation strategies and surveillance system for adverse effects, track status of government approval, and collect real world evidence on value of therapeutic agent

providing an online database featuring tracking the status of government approval of medications

Providing an online database featuring medical information and diagnostics in the nature of pharmaceutical information for developing model-informed precision dosing, tracking individualized dosing, generating population based and individual based pharmacokinetic models, monitoring clinical studies, determining optimal and lowest effective dosages of medication, developing risk evaluation and mitigation strategies and surveillance system for adverse effects, and collecting real world evidence on value of therapeutic agent

Creating, maintaining and hosting an interactive website for others featuring technology that enables users to enter, access, track, and generate health and medical information; creating, maintaining and hosting an interactive website for others featuring technology that enables users to manage chronic diseases, medical conditions, and health risks; creating, maintaining, and hosting an interactive website for others featuring technology that enables users to enter medical information and generate the lowest effective dosage of medication; design and development of software in the field of interactive mobile applications featuring technology that enables users to manage their optimal dosing intervals of medication; Providing temporary use of nondownloadable computer software for use in calculating and tailoring the optimal individualized dosage for patients through blood samples from patients; Providing temporary use of non-downloadable computer software for use in mobile applications to develop model-informed precision dosing, track individualized dosing, generate population- and individual based pharmacokinetic models, monitor clinical studies, determine optimal and lowest effective dosages of medication, develop risk evaluation and mitigation strategies and surveillance system for adverse effects, track status of government approval, and collect real world evidence on value of therapeutic agent

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 30, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 30, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 28, 2025 EXRA
SOU EXTENSION 5 GRANTED
Feb 27, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 27, 2025 AITU
SOU EXTENSION 5 FILED
Nov 19, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 19, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 15, 2024 EXRA
SOU EXTENSION 4 GRANTED
May 14, 2024 EX4G
SOU EXTENSION 4 FILED
May 14, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
May 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 14, 2023 EXRA
SOU EXTENSION 3 GRANTED
Nov 10, 2023 EX3G
SOU EXTENSION 3 FILED
Nov 10, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 10, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2023 EXRA
SOU EXTENSION 2 GRANTED
May 12, 2023 EX2G
SOU EXTENSION 2 FILED
May 12, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
May 12, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 15, 2022 EXRA
SOU EXTENSION 1 GRANTED
Nov 11, 2022 EX1G
SOU EXTENSION 1 FILED
Nov 11, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 11, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 24, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 29, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 29, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 9, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 23, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 19, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 19, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 16, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 25, 2021 NWOS
NEW APPLICATION ENTERED
Jun 5, 2021 NWAP